0.24
+4.44%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cytodyn
From its filings with the US Securities and Exchange Commission
Cytodyn is based in Vancouver, Washington and is incorporated in Delaware. Its shares trade on OTC under the ticker CYDY. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 May 2023, it reported revenue of $0.
CytoDyn Inc. (together with its wholly owned subsidiary, the “Company”) was originally incorporated under the laws of Colorado on May 2, 2002, under the name RexRay Corporation and, effective August 27, 2015, reincorporated under the laws of Delaware. The Company is a clinical-stage biotechnology company focused on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab (also referred to as PRO 140), a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 (“CCR5”). The preclinical and early clinical development of PRO 140 was led by Progenics through 2011. The Company acquired the asset from Progenics in October 2012. In November 2018, the United States Adopted Names Council adopted “leronlimab” as the official nonproprietary name for PRO 140.
The consolidated financial statements included in this Form 10-K include the accounts of CytoDyn Inc. and its wholly owned subsidiary CytoDyn Operations Inc.
The Company is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of its product candidate, leronlimab, which is being studied for its potential in solid-tumor oncology. Leronlimab targets CCR5, a receptor increasingly recognized for its role in tumor progression, metastasis and immune regulation, providing the Company with the opportunity to explore a potentially differentiated therapeutic approach across multiple solid tumor indications.
Quoted from its 10-K, filed 31 Aug 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Nov 2005
- Employees
- 13
- Website
- cytodyn.com ↗
- Head office
- 1111 MAIN STREET, SUITE 660, VANCOUVER, WA, 98660
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Tanya UrbachIndependent Chairman of the Board$188,700
- Dr. Jacob LalezariChief Executive Officer$783,850
- Mr. Robert HoffmanChief Financial Officer$388,526
- Mr. Tyler BlokCorporate Secretary, Chief Legal Officer$532,494
- Dr. Karen BrunkeIndependent Director$138,700
- Mr. Ryan DunlapIndependent Director$156,200
- Dr. Lishomwa NdhlovuIndependent Director$136,200
- Mr. Stephen SimesIndependent Director$156,200
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cytodyn Inc has a strong intellectual property portfolio, which includes various patents and proprietary technologies. This provides the company with a competitive advantage and potential licensing opportunities.
- The company has developed a promising drug pipeline, including potential treatments for HIV, cancer, and other diseases. This diversification helps reduce risks associated with relying on a single product.
Weaknesses
- Cytodyn Inc has a relatively small market presence compared to larger pharmaceutical companies. This may limit its marketing and distribution capabilities, making it challenging to compete on a global scale.
- The company heavily relies on external funding to finance its research and development efforts, which exposes it to financial risks and uncertainties.
Opportunities
- The increasing prevalence of HIV and cancer worldwide presents a significant market opportunity for Cytodyn Inc's potential drugs. The growing demand for innovative treatments and therapies opens doors for the company to capture market share.
- Collaborations with other pharmaceutical companies or research institutions can provide access to additional resources, expertise, and funding, enabling the company to accelerate its drug development and expand its product portfolio.
Threats
- The pharmaceutical industry is highly competitive, with rapid advancements in technologies and treatments. Cytodyn Inc faces the risk of larger competitors developing similar or superior drugs, thus limiting its market potential.
- Regulatory requirements and approval processes for new drugs can be time-consuming and costly. Failure to obtain necessary approvals or encountering regulatory hurdles may delay the commercialization of Cytodyn Inc's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.